Global Infection Prevention Product and Services Market Size, Share, Opportunities, And Trends By Infection Prevention Product and Services (Gloves, Surgical Drapes, Gowns, Face Masks, Protective Apparels, Sterilization Products, Disinfectants, Infection Prevention Services), By End User (Hospitals, Clinics, Ambulatory Surgery Centers, Diagnostic Centers, Life Sciences and Biomedical Research Organization), And By Geography- Forecasts From 2025 To 2030

The global infection prevention product and services market was valued at US$171.502 billion in 2025, and it is anticipated to grow to US$225.847 billion in 2030, with a CAGR of 5.66%.

The growing number of acute and chronic diseases is propelling the market growth in the forecast period. Chronic diseases include cardiovascular diseases, the prevalence of cancer, asthma, and COPD, among others. Concerns regarding hospital-associated infections, surgical-site infections, and medical waste disposal are allowing the market to increase in the forecast period and the coming years.

The increasing awareness of infection control across healthcare settings, growing healthcare-associated infections (HAIs) and the elderly population with weakened immune systems are factors driving the global infection prevention products and services market. Governments and regulatory bodies worldwide are enforcing strict infection control protocols, increasing the demand for sterilization equipment, disinfectants, and personal protective equipment (PPE). The rising number of chronic diseases and invasive procedures drive the market as hospitals and clinics embrace advanced infection prevention solutions.

What are the Global Infection Prevention Product and Services Market Drivers?

• The prevalence of healthcare services will drive the infection prevention product and services market in the coming years.

Healthcare services categorized as primary care, secondary care, tertiary care, and quaternary care are driving the market during the forecast period. Primary care involves healthcare professionals who play a role in the local community. This provides care to patients of all ages from different socioeconomic and geographic regions. Various chronic illnesses can be treated under primary care, including hypertension, diabetes, depression, and anxiety. The professionals involved in primary care would usually be general practitioners or family doctors. Other professionals include nurses or physiotherapists. The key characteristic of primary care is continuity, consisting of routine check-ups and preventive care. Depending on the patient's condition, he/she may be advised for secondary or tertiary care.

Secondary care includes the treatment of serious illnesses that require immediate action for a shorter period. One can find this kind of facility in the hospital's emergency department, which requires skilled professionals and attendants. Tertiary care is for specialized healthcare services. The patients are referred via primary and secondary care and require advanced medical investigation and treatment facilities. Examples include cardiac and other complex surgeries. Quaternary care is an extension of tertiary care and makes use of advanced and highly specialized treatments and care. These are not widely accessible but still provide a favorable growth opportunity for the market in the forecast period.

• The presence of the geriatric population in the world is projected to drive the market in the forecast period.

The growing geriatric population has given rise to an increase in healthcare costs required for the treatment of non-communicable diseases and chronic diseases related to old age.

The aging population, particularly those over 65, is raising concerns about the pressure on health systems. These systems must adapt to accommodate the increasing demand for care, services, and technologies for preventing and treating age-related non-communicable and chronic diseases. For instance, according to the World Economic Forum, more than 1 in 10 people in Japan are now older than 60. Almost two-thirds of the population, or an estimated 36.23 million people aged more than 65 years in 2023. 

Similarly, according to the Administration for Community Living (ACL) in the United States, in 2022, 57.8 million people aged 65 years or older in the country. They constitute 17.3% of the population, more than 1 in every 6 Americans. Since 2012, the number of older Americans has grown by 34% (14.7 million), compared with an increase of 2% in the population under 65. Hence, the increasing older population in various countries is expected to positively influence the global infection prevention products and services market in the projected period. 

Additionally, as non-communicable diseases and the potential economic & societal costs of these diseases rise with age, they can also affect economic growth. Hence, the growing geriatric population will greatly impact this global market’s growth over the next five years. With the increasing elderly population, there is a significant increase in home healthcare services. Thus, this will further surge the market growth in the coming years.

Segment Analysis of the Global Infection Prevention Product and Services Market:

• By end-user segment, the hospital sector is anticipated to hold a significant market share in the projected period. 

The global infection prevention products and services market by end-user is segmented into hospitals, clinics, ambulatory surgery centers (ASCs), diagnostic centers, and life sciences & biomedical research organizations. Hospitals have a major market share due to the high volume of patients, complex procedures, and stringent infection control protocols required to prevent HAIs. 

Clinics also contribute significantly, especially in outpatient care, where proper infection prevention is crucial to protecting patients and staff. Ambulatory surgery centers are experiencing increased demand for sterilization and disinfection products as outpatient surgeries increase. 

Diagnostic centers use infection prevention products to ensure that testing is done in a sterile environment and to protect the patient. Life sciences and biomedical research organizations require stringent measures for contamination control to protect research integrity and comply with regulatory standards, which in turn increases the demand for sophisticated infection prevention solutions. The diverse end-user landscape indicates that infection control is critical for healthcare and research settings across all spectrums.

North America is predicted to hold significant market share

Based on geography, North America is estimated to hold a significant market share due to the presence of advanced health facilities. Efforts are made to maintain these facilities, emphasizing infection prevention and control. Additionally, the presence of prominent market players in the region is further increasing the demand in the forecast period and the coming years. 

On the other hand, the Asia Pacific market is growing rapidly due to the high prevalence of chronic diseases that demand treatment. With the highest number of geriatric populations in Japan, the APAC region holds strong prospects for the market to grow significantly in the forecast period.  

Furthermore, the booming medical tourism industry and the growing number of surgeries and minimally invasive and robotic surgeries are propelling the market expansion in the forecast period.

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.1.1. Growing Demand for Packaging

4.1.2. Increasing Focus on Sustainability

4.2. Market Restraints

4.2.1. Environmental Concerns

4.2.2. High Production Cost

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. The Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. GLOBAL INFECTION PREVENTION PRODUCT AND SERVICES MARKET BY PRODUCTS AND SERVICES 

5.1. Introduction

5.2. Gloves

5.2.1. Medical Laboratory Gloves

5.2.2. Examination Gloves

5.2.3. Surgical Gloves

5.3. Surgical Drapes

5.4. Gowns

5.4.1. Surgical Gowns

5.4.2. Patient Gowns

5.5. Face Masks

5.5.1. Surgical Masks

5.5.2. Healthcare Staff Masks (Medical-Grade)

5.6. Protective Apparel

5.6.1. Disposable Staff Apparel

5.6.2. Disposable Towels and Bedding

5.7. Sterilization Products

5.7.1. Sterile Containers

5.7.2. Sterilization Wrap

5.7.3. Sterilization Indicators

5.7.4. Sterilization Equipment

5.8. Disinfectants

5.8.1. Surface

5.8.2. Surgical

5.8.3. Instrument

5.8.4. Hand Sanitizers

5.8.5. Disinfecting Equipment

5.9. Infection Prevention Services

5.9.1. Medical Waste Disposal Services

5.9.2. Contract Sterilization and Decontamination Services

6. GLOBAL INFECTION PREVENTION PRODUCT AND SERVICES MARKET BY END-USER

6.1. Introduction

6.2. Hospitals

6.3. Clinics

6.4. Ambulatory Surgery Centers

6.5. Diagnostic Centers

6.6. Life Sciences and Biomedical Research Organization

7. GLOBAL INFECTION PREVENTION PRODUCT AND SERVICES MARKET BY GEOGRAPHY

7.1. Introduction

7.2. North America

7.2.1. United States

7.2.2. Canada

7.2.3. Mexico

7.3. South America

7.3.1. Brazil

7.3.2. Argentina

7.3.3. Others

7.4. Europe

7.4.1. UK

7.4.2. Germany

7.4.3. France

7.4.4. Spain

7.4.5. Italy

7.4.6. Others

7.5. Middle East and Africa

7.5.1. United Arab Emirates

7.5.2. Israel

7.5.3. Saudi Arabia

7.5.4. Others

7.6. Asia Pacific

7.6.1. Japan

7.6.2. China

7.6.3. India

7.6.4. Australia

7.6.5. Indonesia

7.6.6. Thailand

7.6.7. Malaysia

7.6.8. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Emerging Players and Market Lucrativeness

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

9.1. STERIS

9.2. Advanced Sterilization Products, Inc.

9.3. Ahlstrom-Munksjö

9.4. ANSELL LTD.

9.5. Becton, Dickinson and Company

9.6. B. Braun Melsungen AG

9.7. Cardinal Health

9.8. Mölnlycke Health Care AB

9.9. Getinge AB

9.10. 3M

STERIS

Advanced Sterilization Products, Inc.

Ahlstrom-Munksjö

ANSELL LTD.

Becton, Dickinson and Company

B. Braun Melsungen AG

Cardinal Health

Mölnlycke Health Care AB

Getinge AB

3M